[go: up one dir, main page]

Quinones et al., 1984 - Google Patents

Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral …

Quinones et al., 1984

Document ID
12163249089533778143
Author
Quinones R
Youle R
Kersey J
Zanjani E
Azemove S
Soderling C
Lebien T
Beverley P
Neville Jr D
Vallera D
Publication year
Publication venue
The Journal of Immunology

External Links

Snippet

Three murine anti-human monoclonal antibodies broadly reactive with human T cells were conjugated to intact ricin toxin. The purgative effects of these immunotoxins (IT) on alloreactive T cells after in vitro pretreatment was tested in an in vitro assay measuring the …
Continue reading at academic.oup.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
    • A61K47/48515—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups
    • A61K47/48561—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups the antibody being targeting a receptor, a cell surface antigen, a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Landay et al. Characterization of a phenotypically distinct subpopulation of Leu-2+ cells that suppresses T cell proliferative responses.
Filipovich et al. Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease
Horwitz et al. Distinctive functional properties of human blood L lymphocytes: a comparison with T lymphocytes, B lymphocytes, and monocytes
Phillips et al. Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu-11 and class II histocompatibility antigens.
Janossy et al. Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies.
EP0097518B1 (en) Monoclonal antibody
CA1214124A (en) Monoclonal antibody covalently linked to the toxin ricin
Neville Jr et al. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9
EP0294703B1 (en) Bifunctional antibody constructs and method for selectively destroying cell populations
Uckun et al. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow.
Welte et al. OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells.
Siena et al. Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates
Quinones et al. Anti-T cell monoclonal antibodies conjugated to ricin as potential reagents for human GVHD prophylaxis: effect on the generation of cytotoxic T cells in both peripheral blood and bone marrow.
Fox et al. A novel cell surface antigen (T305) found in increased frequency on acute leukemia cells and in autoimmune disease states.
AU678179B2 (en) Methods for positive immunoselection of stem cells
Coombes et al. In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer
Stong et al. Elimination of clonogenic T-leukemic cells from human bone marrow using anti-M r 65,000 protein immunotoxins
Haagen et al. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2
Keever et al. Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow
Colombatti et al. Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: comparison of cytotoxic potency and use in immunoselection procedures.
Preffer et al. Two-color flow cytometry and functional analysis of lymphocytes cultured from human renal allografts: identification of a Leu-2+ 3+ subpopulation.
Manske et al. Antigenic modulation by anti-CD5 immunotoxins.
Taniyama et al. Establishment of a hybridoma secreting a monoclonal antibody specific for activated tumoricidal macrophages.
BERENsoN et al. CELLULAR IMMUNOABSORPTION USING MONOCLONAL ANTIBODIES: ELECTIVE REMOVAL OF T CELLS FROM PERIPHERAL BLOOD AND BONE MARROW
Cazzola et al. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors